Cyclacel Pharmaceuticals, Inc. (CYCC)'s Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential And Synergy With Other Anti-Cancer Compounds 4/20/2015

Press/Media: Press / Media

PeriodApr 20 2015

Media coverage

1

Media coverage

  • TitleCyclacel Pharmaceuticals, Inc. (CYCC)'s Second-Generation CDK2/9 Inhibitor, CYC065, Demonstrates Therapeutic Potential And Synergy With Other Anti-Cancer Compounds 4/20/2015
    Media name/outletClinicSpace
    CountryCanada
    Date4/20/15
    PersonsJing Wang